We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Medical

Stablepharma

Status: Active

May 6th 2019 - Jul 3rd 2019

Stablepharma invents a disruptive solution that can eliminate waste and supply life-saving vaccines without refrigeration. It is a patented invention that allows vaccines to be stored for years and transported without refrigeration whilst adhering with the protocols established by the WHO. Its current project plan comprises the Tetanus vaccine processed by Clinical Trials in Humans. The success of this project will significantly enhance the value of the invention and allow it to set up a pilot scale production in the $36 bn human vaccine market.

read more read less
Log in to view amount pledged

    Log in to view target

    £10,000,000
    pre-money valuation

    6.98%
    equity available

    524
    investors

    £2,500
    pledge per investor

    07925414
    company number

    Active
    company status

    26/01/2012
    incorporated 12 years

    Equity Calculator
    ?>
    Investment
    £
    Equity
    %
    Previous Funding rounds
    03 May 24 Crowdcube £1,310,090 / 175%

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


Log in to view amount pledged

    Log in to view target

    £10,000,000
    pre-money valuation

    6.98%
    equity available

    524
    investors

    £2,500
    pledge per investor

    07925414
    company number

    Active
    company status

    26/01/2012
    incorporated 12 years

    Equity Calculator
    ?>
    Investment
    £
    Equity
    %
    Previous Funding rounds
    03 May 24 Crowdcube £1,310,090 / 175%
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph